Is Tela Bio Stock a Good Investment?

Tela Bio Investment Advice

  TELA
To provide specific investment advice or recommendations on Tela Bio stock, we recommend investors consider the following general factors when evaluating Tela Bio. This will help you to make an informed decision on whether to include Tela Bio in one of your diversified portfolios:
  • Examine Tela Bio's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
  • Research Tela Bio's leadership team and their track record. Good management can help Tela Bio navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
  • Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Tela Bio's business and its evolving consumer preferences.
  • Compare Tela Bio's performance and market position to its competitors. Analyze how Tela Bio is positioned in terms of product offerings, innovation, and market share.
  • Check if Tela Bio pays a dividend and its dividend yield and payout ratio.
  • Review what financial analysts are saying about Tela Bio's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Tela Bio stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Tela Bio is a good investment.
 
Sell
 
Buy
Strong Sell
We provide advice to complement the current expert consensus on Tela Bio. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Tela Bio is not overpriced, please validate all Tela Bio fundamentals, including its cash and equivalents, cash flow from operations, and the relationship between the gross profit and debt to equity . Given that Tela Bio has a number of shares shorted of 335.91 K, we advise you to double-check Tela Bio market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your current risk tolerance and investing horizon.

Market Performance

WeakDetails

Volatility

Out of controlDetails

Hype Condition

Under hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

Very HighDetails

Economic Sensitivity

Almost neglects market trendsDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

Strong BuyDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

UnavailableDetails

Examine Tela Bio Stock

Researching Tela Bio's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 52.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.69. Tela Bio had not issued any dividends in recent years.
To determine if Tela Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tela Bio's research are outlined below:
Tela Bio had very high historical volatility over the last 90 days
Tela Bio has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 58.45 M. Net Loss for the year was (46.66 M) with profit before overhead, payroll, taxes, and interest of 27.85 M.
Tela Bio currently holds about 27.73 M in cash with (40.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.9.
Latest headline from gurufocus.com: TELA Bio to Participate in Piper Sandlers 36th Annual Healthcare Conference

Tela Bio Quarterly Accounts Payable

2.48 Million

Tela Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tela Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tela Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
19th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
19th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View
Earnings surprises can significantly impact Tela Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Tela Bio's investors have experienced.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-03-24
2020-12-31-0.49-0.54-0.0510 
2020-08-12
2020-06-30-0.59-0.530.0610 
2023-08-09
2023-06-30-0.53-0.460.0713 
2023-05-11
2023-03-31-0.56-0.63-0.0712 
2020-05-12
2020-03-31-0.56-0.63-0.0712 
2021-05-13
2021-03-31-0.48-0.56-0.0816 
2024-03-21
2023-12-31-0.43-0.53-0.123 
2022-08-10
2022-06-30-0.62-0.79-0.1727 

Know Tela Bio's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Tela Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tela Bio backward and forwards among themselves. Tela Bio's institutional investor refers to the entity that pools money to purchase Tela Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Pentwater Capital Management Lp2024-09-30
500 K
Millennium Management Llc2024-06-30
404.6 K
Perkins Capital Management Inc2024-09-30
225.2 K
Geode Capital Management, Llc2024-09-30
174.5 K
Goldman Sachs Group Inc2024-06-30
153.7 K
Renaissance Technologies Corp2024-09-30
148.9 K
Landscape Capital Management,llc2024-09-30
143.2 K
Gsa Capital Partners Llp2024-09-30
112.2 K
State Street Corp2024-06-30
107.4 K
Essex Woodlands Health Ventures2024-09-30
4.1 M
Aigh Capital Management, Llc2024-09-30
2.5 M
Note, although Tela Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Tela Bio's market capitalization trends

The company currently falls under 'Small-Cap' category with a current market capitalization of 119.35 M.

Market Cap

113.62 Million

Tela Bio's profitablity analysis

Last ReportedProjected for Next Year
Return On Tangible Assets(0.61)(0.65)
Return On Capital Employed(0.72)(0.76)
Return On Assets(0.60)(0.63)
Return On Equity(2.47)(2.60)
The company has Profit Margin (PM) of (0.6) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.49) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.49.
Determining Tela Bio's profitability involves analyzing its financial statements and using various financial metrics to determine if Tela Bio is a good buy. For example, gross profit margin measures Tela Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Tela Bio's profitability and make more informed investment decisions.
Please note, the presentation of Tela Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tela Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Tela Bio's management manipulating its earnings.

Evaluate Tela Bio's management efficiency

Tela Bio has return on total asset (ROA) of (0.4064) % which means that it has lost $0.4064 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4204) %, meaning that it created substantial loss on money invested by shareholders. Tela Bio's management efficiency ratios could be used to measure how well Tela Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.65. In addition to that, Return On Capital Employed is expected to decline to -0.76. At present, Tela Bio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 278.2 K, whereas Total Assets are forecasted to decline to about 63.7 M.
Last ReportedProjected for Next Year
Book Value Per Share 0.83  0.87 
Tangible Book Value Per Share 0.73  0.77 
Enterprise Value Over EBITDA(3.59)(3.77)
Price Book Value Ratio 8.02  4.30 
Enterprise Value Multiple(3.59)(3.77)
Price Fair Value 8.02  4.30 
Enterprise Value131.2 M104.1 M
The decision-making processes within Tela Bio are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta
0.968

Basic technical analysis of Tela Stock

As of the 29th of November, Tela Bio has the Risk Adjusted Performance of 0.0307, semi deviation of 2.67, and Coefficient Of Variation of 3339.4. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tela Bio, as well as the relationship between them.

Tela Bio's insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tela Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tela Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tela Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Blizard Jeffrey over two months ago
Acquisition by Blizard Jeffrey of 6375 shares of Tela Bio subject to Rule 16b-3
 
Peter Murphy over two months ago
Acquisition by Peter Murphy of 19300 shares of Tela Bio at 7.07 subject to Rule 16b-3
 
Gregory Firestone over three months ago
Disposition of 1093 shares by Gregory Firestone of Tela Bio at 4.25 subject to Rule 16b-3
 
Antony Koblish over three months ago
Acquisition by Antony Koblish of 113200 shares of Tela Bio at 7.07 subject to Rule 16b-3
 
Orbimed Advisors Llc over three months ago
Disposition of 36600 shares by Orbimed Advisors Llc of Tela Bio at 4.54 subject to Rule 16b-3
 
Orbimed Advisors Llc over three months ago
Disposition of 36600 shares by Orbimed Advisors Llc of Tela Bio at 4.54 subject to Rule 16b-3
 
Orbimed Advisors Llc over three months ago
Disposition of 13700 shares by Orbimed Advisors Llc of Tela Bio at 4.68 subject to Rule 16b-3
 
Orbimed Advisors Llc over three months ago
Disposition of 378000 shares by Orbimed Advisors Llc of Tela Bio at 4.74 subject to Rule 16b-3
 
Azarbarzin Kurt over three months ago
Acquisition by Azarbarzin Kurt of 5360 shares of Tela Bio at 10.34 subject to Rule 16b-3
 
Ew Healthcare Partners Fund 2, L.p. over six months ago
Acquisition by Ew Healthcare Partners Fund 2, L.p. of 25000 shares of Tela Bio at 8.25 subject to Rule 16b-3
 
Gregory Firestone over six months ago
Disposition of 119 shares by Gregory Firestone of Tela Bio at 5.67 subject to Rule 16b-3
 
Paul Talmo over six months ago
Acquisition by Paul Talmo of 16800 shares of Tela Bio subject to Rule 16b-3

Tela Bio's Outstanding Corporate Bonds

Tela Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tela Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tela bonds can be classified according to their maturity, which is the date when Tela Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Understand Tela Bio's technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Tela Bio's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

Consider Tela Bio's intraday indicators

Tela Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tela Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Tela Bio Corporate Filings

13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
10Q
8th of November 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
8K
7th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
29th of October 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
Tela Bio time-series forecasting models is one of many Tela Bio's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tela Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Tela Stock media impact

Far too much social signal, news, headlines, and media speculation about Tela Bio that are available to investors today. That information is available publicly through Tela media outlets and privately through word of mouth or via Tela internal channels. However, regardless of the origin, that massive amount of Tela data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tela Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tela Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tela Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tela Bio alpha.

Tela Bio Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Tela Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Tela Bio Corporate Management

Megan SmeykalCorporate VPProfile
Taylor OcasioGeneral SecretaryProfile
Antony KoblishPresident, CofounderProfile
Louisa SmithInvestor OfficerProfile
Skott GreenhalghChief OfficerProfile
Peter MurphyChief OfficerProfile
Roberto JDCFO COOProfile
When determining whether Tela Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tela Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tela Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tela Bio Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tela Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Tela Stock refer to our How to Trade Tela Stock guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tela Bio. If investors know Tela will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tela Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.69)
Revenue Per Share
2.789
Quarterly Revenue Growth
0.259
Return On Assets
(0.41)
Return On Equity
(3.42)
The market value of Tela Bio is measured differently than its book value, which is the value of Tela that is recorded on the company's balance sheet. Investors also form their own opinion of Tela Bio's value that differs from its market value or its book value, called intrinsic value, which is Tela Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tela Bio's market value can be influenced by many factors that don't directly affect Tela Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Tela Bio's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Tela Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tela Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.